NAGLAZYME: Charting a new course NAGLAZYME® (galsulfase) is indicated for patients with mucopolysaccharidosis VI (MPS VI). NAGLAZYME has been shown to improve walking and stair-climbing capacity. NAGLAZYME: The first-line treatment for patients with MPS VI Enzyme replacement therapy (ERT) is a treatment approach for diseases whose complications are caused by an enzyme deficiency. In ERT, the deficient human enzyme is replaced with its recombinant equivalent. An entirely new approach, ERT promises patients a hopeful new future. Disease-focused therapy Enzyme replacement therapy (ERT) with NAGLAZYME is a disease-specific treatment designed to address the deficiency of enzyme activity and pathophysiological processes in MPS VI. ERT with NAGLAZYME provides cells with a recombinant version of arylsulfatase B (ASB), the deficient human enzyme that can degrade GAG.2 Patients receiving regular intravenous infusions have experienced significant clinical benefits. In clinical trials, NAGLAZYME has shown efficacy and demonstrated an acceptable safety profile.2 To maximize efficacy of NAGLAZYME, early diagnosis and consistent compliance are important. Learn more about MPS VI treatment